You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • AB0590 Rates of treatment continuation and remission in 97 patients with high c-reactive protein receiving tocilizumab: 2-year study based on the tsurumai biologics communication registry

Article info

Article menu
Download PDFPDF
Scientific Abstracts
Abstracts accepted for publication
Rheumatoid arthritis – other biologic treatment
AB0590 Rates of treatment continuation and remission in 97 patients with high c-reactive protein receiving tocilizumab: 2-year study based on the tsurumai biologics communication registry

Authors

Citation

Yabe Y, Kojima T, Kaneko A, et al
AB0590 Rates of treatment continuation and remission in 97 patients with high c-reactive protein receiving tocilizumab: 2-year study based on the tsurumai biologics communication registry
Annals of the Rheumatic Diseases 2013;71:672.

Publication history

  • First published January 23, 2014.
Online issue publication 
April 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2013, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions